Beneficial effect of adding pentoxifylline to processed semen samples on ICSI outcome in infertile males with mild and moderate asthenozoospermia: A randomized controlled prospective crossover study

Medhat Amer1,2 M.D., Bahgat Metawae1 M.D., Hosam Hosny1 M.D., Ahmad Raef1 M.D.

Abstract
Background: No extensive studies were done that included the use of pentoxifylline or verify its effect on the outcome of ICSI in cases of mild and moderate asthenozoospermia.

Objective: The aim of this study was to evaluate the effect of pentoxifylline used in preparation of semen samples which doesn’t need motility enhancement prior to ICSI.

Materials and Methods: The study was carried on 30 infertile patients where pentoxifylline was used for semen processing (group I), another 30 patients without pentoxifylline (group II) in addition to 60 infertile patients where crossing over of the semen sample was done further subdividing it into 2 subgroups in which the first half of the semen sample was incubated with pentoxifylline (group IIIA) and the second half of the sample without pentoxifylline (group IIIB).

Results: The numbers of oocytes injected, numbers of oocytes fertilized, fertilization rate, the total numbers of embryos, numbers of good embryos and the numbers of embryos transferred of group IIIA were found significantly higher than that of Group IIIB (p=0.00). The overall 6 month pregnancy rate of group I was significantly higher than that of group II (73.3% vs. 60% respectively, p=0.04). The abortion rate of (Group I) and that of (Group II) was found non – significantly different (20% vs. 27.8% respectively, p=0.53).

Conclusion: Pentoxifylline can be used as a useful compound for improving ICSI outcome in semen samples preparation prior to oocytes injection regardless of the state of sperm motility or the degree of asthenozoospermia.

Key words: Pentoxifylline, Intracytoplasmic sperm injections, Asthenozoospermia.

Registration ID in Clinical Trials.gov: NCT01793272

Introduction

Pentoxifylline (PTX) is a non-specific phosphodiesterase (PDE) inhibitor of the methylxantine group, it inhibits the breakdown of cyclic adenosine monophosphate (cAMP) and it is known that intracellular cAMP concentration plays a central role in sperm motility (1). The molecular basis of cAMP regulation is based on protein phosphorylation, especially for capacitation as (2).

The typical protocol for PTX use involves a 30 minutes preincubation of prepared sperm with stimulant (PTX at 1-5 mmol/l), sperm is then washed to remove the stimulant and is used immediately for ova fertilization (3). Apart from the effects on sperm motility, Tesarik et al reported that PTX augments the acrosome reaction (4). No extensive studies were done that included the use of pentoxifylline or verify its effect on the outcome of ICSI in cases of mild and moderate asthenozoospermia, although extensive studies were done on its effect in cases of severe male factor, severe oligozoospermia or severe asthenozoospermia particularly in IVF cycles.

Rizk et al in a study on IVF cycles found that a significantly higher fertilization rate occurred in the group were oocytes were inseminated with spermatozoa treated with PTX compared with controls (5). Imoedemhe et al showed an increase in sperm motility but a significant decrease in the fertilization rates and embryo development (6). Sohn et al reported that the fertilization rate and clinical pregnancy of PTX group was higher than
those of ICSI programs undertaken using sperm not treated with PTX (7).

Takeda et al found that fertilization and embryo recovery rates of the PTX group were significantly lower than those of the control group in cases of severe oligozoospermia (8). Therefore, this randomized prospective crossover study was performed to demonstrate, for the first time in literature, the beneficial effect of PTX used in preparation of semen samples that will be used for ICSI in infertile men complaining of mild and moderate asthenozoospermia in comparison to semen samples without PTX preparation on the outcome of ICSI.

Materials and methods

Study population

This study recruited 150 subjects, from October 2010 to April 2011, from males attending the Andrology Clinic in a specialized center for assisted reproduction techniques (Adam International Hospital, Giza, Egypt) seeking ICSI for primary or secondary infertility as shown in the consort flow diagram 2010 (Figure 1). All patients were provided with a thorough history taking, both present and past, general and local genital examination, conventional semen analysis according to WHO 2010 standards, and referral of the patient’s wife to the gynecology and obstetrics unit in the same center for through assessment and preparation for ICSI (9).

Any patient with following criteria was excluded from participating in the study: Semen profile showing pyospermia, presence of antisperm antibodies, azoospermia, severe male factor, oligozoospermia or severe asthenozoospermia. Wife’s age >35 years. Low antral count. Presence of any ovarian factor contributing to infertility e.g. PCO. Past history of orchitis. Patients who received empirical treatment for asthenozoospermia e.g. oral PTX, l-carnitine or antioxidants during the past 3-6 month. Diabetics, hypertensives or patients with any other chronic systemic illnesses.

After excluding 30 subjects due to one or more of the previously mentioned exclusion criteria, 120 males were included in the study with semen showing mild or moderate asthenozoospermia and they were prospectively randomized and divided into 3 groups:

a. Group (I): consisted of 30 patients where semen sample was incubated with PTX on the day of ova pickup prior to ICSI.

b. Group (II): consisted of 30 patients where semen sample was processed without using PTX on the day of ova pickup prior to ICSI.

c. Group (III): consisted of 60 patients where cross over was done as the semen sample obtained from each patient on day of ova pickup was divided equally into two parts, further subdividing these patients into 2 subgroups: Group (IIIA) PTX-treated semen portion and Group (IIIB) non-PTX treated control semen portion and the wife’s ova was divided over these 2 parts for fertilization.

Study design

The study randomization was performed using computer generated random numbers for each patient presenting at the Andrology Clinic in the hospital and informed consent was obtained from all patients and after receiving a detailed explanation from the physician according to the regulations of the “Andrology Department Ethical Committee, Faculty of Medicine, Cairo University”.

Study protocol

Female partners were prepared by the long controlled ovarian stimulation protocol after performing the general, reproductive and hormonal evaluations of the patient. Cumulus-corona-oocyte complexes were retrieved by vaginal ultrasound-guided puncture of the ovarian follicles performed 35 hours after human chorionic gonadotrophin (HCG, Choriomon, IBSA) administration when the criteria for oocyte maturity were met as stated by Palermo et al (10). Two hours after collection, the oocytes were treated by 0.5% hyaluronidase (Hyase, Ferti Pro) for 10 seconds for enzymatic removal of the cumulus oophorus cells using a sterile yellow tip.

Under stereomicroscopic guidance at x50 magnification, cells of the corona radiata were removed mechanically with aid of 140 um cook stripper (Cook, Australia) for fine denaturation, then the maturity of the oocytes was determined, only oocytes in metaphase II were injected as shown by Ola et al (11). Pentoxifylline (Trental ®) 100mg/ 5ml ampoules (Sanati Aventis, Istanbul, Turkey) was used where 20 microns were aspirated by pipette and dissolved in either Earl’s Buffered Solution (EBS, GIBCO®) or Human Tubal
Fluid (HTF, Irvine Scientific®) medium, then solution was incubated with freshly collected semen sample at 37°C and was ready for ova fertilization after about 5 minutes.

The preparation of the holding and injection pipettes, and the injection procedure itself, were described by Al-Hasani et al (12). Sixteen to eighteen hours after injection and incubation in 20 ul microdrops of medium under Sage cleavage culture medium and Sage oil as demonstrated by Quinn, for tissue culture at 37°C in a humidified atmosphere with 6% CO₂ and 5% O₂; the oocytes were examined for the presence of pronuclei and polar bodies as shown by Tesarik and Greco (13, 14). The embryos were monitored exactly 48 hours for 4 cell stage (day 2 transfer), or exactly 72 hours for 7-9 cell stage (day 3 transfer), or blastocyst stage (day 5 transfer). Embryo scoring was based on the following criteria:

A-Blastomere number (cleavage rate), B-Fragmentation percentage and C-fragmentation pattern. Each item given certain number of points and the cumulative embryo score was determined by (blastomere number points X fragmentation % points± extrapoints). Good embryo took 15-20 points, fair embryos took 10-15 while poor embryos took 0-10 points according to the findings of Alikani et al (15).

Luteal support was provided with Prontogest (IBSA, Switzerland) until the pregnancy test was performed by measuring the serum HCG concentration on at least two separate occasions, 2 weeks after embryo transfer. Clinical pregnancy was determined by ultrasound screening of the fetal sac, fetal pole and cardiac beat after 3 weeks for patients with positive pregnancy test. Pregnancy was monitored during the following 6 month by the obstetrician and the final outcome was reported to the clinic.

**Study end-points**

The primary outcome measures were the number of oocytes retrieved, the number of oocytes injected, number of oocytes fertilized, fertilization rate, number of embryos and their quality (G1: good embryos, G2: fair embryos and G3: poor embryos), number of embryos transferred (ET), number of embryo sacs, embryo implantation rate, pregnancy rate and abortion rate for all 3 groups and pregnancy rate and abortion rate for both group I and group II.

**Statistical analysis**

Student T-test, Chi-square test, Mann-Whitney U-test were used for comparing data from all groups. Results were expressed as means, standard deviation (SD). Statistical significance was accepted at a p<0.05.

---

**Figure 1.** Consort flow diagram.

**Assessed for eligibility (n= 150)**
- Excluded (n= 30)
  - Not meeting inclusion criteria (n=30)
  - Declined to participate (n=0)
  - Other reasons (n=0)

**Randomized (n= 120)**
- Allocated to intervention (n= 60)
  - Received allocated intervention (n= 60)
  - Did not receive allocated intervention (give reasons) (n= 0)

**Analysis**
- Analysed (n= 60)
  - Excluded from analysis (give reasons) (n= 0)

---

**Enrollment**

- Allocated to intervention (n= 60)
  - Received allocated intervention (n= 60)
  - Did not receive allocated intervention (give reasons) (n= 0)

**Follow-Up**
- Lost to follow-up (give reasons) (n= 0)
  - Discontinued intervention (give reasons) (n= 0)

---

**Allocation**

- Allocated to intervention (n= 60)
  - Received allocated intervention (n= 60)
  - Did not receive allocated intervention (give reasons) (n= 0)

---

**Analysis**
- Analysed (n= 60)
  - Excluded from analysis (give reasons) (n= 60)
Results

Using Mann-Whitney test, the fertilization rate, number of good embryos, number of fair embryos, number of embryos transferred, number of embryos sacs and the implantation rate of group I patients and those of group II patients were found non-significantly different (p=0.935, 0.377, 0.833, 0.755, 0.091 and 0.132 respectively). The numbers of oocytes retrieved, numbers of oocytes injected, numbers of oocytes fertilized, numbers of poor embryos and the total numbers of embryos of group II patients were found higher than that of group I patients and the difference was significant (p=0.005, 0.007, 0.02, 0.004 and 0.028 respectively).

Using Chi-Square test, the pregnancy rates (Table I) and abortion rates of group I was compared to that of group II. The pregnancy rate of group I patients (73%, 22 patients) was found higher than that of group II patients (60%, 18 patients) and the difference was significant. The abortion rate of group I patients (20%, 6 patients) was found lower than that of group II patients (27.8%, 5 patients) but the difference was non-significant. Using Student t-test and paired sample tests (Table II) the numbers of oocytes injected, numbers of oocytes fertilized, fertilization rate (Figure 2), the total numbers of embryos, numbers of good embryos and the numbers of embryos transferred of group IIIA were found higher than that of group IIIB and the difference was significant. The numbers of fair embryos and the numbers of poor embryos of group IIIA and those of group IIIB were found non-significantly different.

Table I. Comparing group I with group II regarding pregnancy rates

<table>
<thead>
<tr>
<th>Pregnancy</th>
<th>Group</th>
<th>Group</th>
<th>Total</th>
<th>p-value sig. (2-tailed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count</td>
<td>22</td>
<td>18</td>
<td>40</td>
<td>0.0473</td>
</tr>
<tr>
<td>% within pregnancy</td>
<td>55.0%</td>
<td>45.0%</td>
<td>100.0%</td>
<td></td>
</tr>
<tr>
<td>% within group</td>
<td>73.3%</td>
<td>60.0%</td>
<td>66.7%</td>
<td></td>
</tr>
</tbody>
</table>

Using Chi-Square test, the pregnancy rates and abortion rates of group I was compared to that of group II.

Table II. Comparing group IIIA with group IIIB

<table>
<thead>
<tr>
<th>Pair</th>
<th>N</th>
<th>Mean</th>
<th>SD</th>
<th>SE mean</th>
<th>p-value sig. (2-tailed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pair 1</td>
<td>Oocytes injected PTX</td>
<td>60</td>
<td>7.4333</td>
<td>2.41722</td>
<td>0.31206</td>
</tr>
<tr>
<td></td>
<td>Oocytes injected</td>
<td>60</td>
<td>7.1500</td>
<td>2.60914</td>
<td>0.33684</td>
</tr>
<tr>
<td>Pair 2</td>
<td>Fertilized oocytes PTX</td>
<td>60</td>
<td>5.5167</td>
<td>2.37567</td>
<td>0.30670</td>
</tr>
<tr>
<td></td>
<td>Fertilized oocytes</td>
<td>60</td>
<td>5.0167</td>
<td>2.76474</td>
<td>0.35693</td>
</tr>
<tr>
<td>Pair 3</td>
<td>Fertilization rate PTX</td>
<td>60</td>
<td>72.5183</td>
<td>18.20812</td>
<td>2.35066</td>
</tr>
<tr>
<td></td>
<td>Fertilization rate</td>
<td>60</td>
<td>66.1600</td>
<td>24.85231</td>
<td>3.20842</td>
</tr>
<tr>
<td>Pair 4</td>
<td>Embryo number PTX</td>
<td>60</td>
<td>4.5000</td>
<td>1.91780</td>
<td>0.24759</td>
</tr>
<tr>
<td></td>
<td>Embryo number</td>
<td>60</td>
<td>3.6167</td>
<td>2.27806</td>
<td>0.29430</td>
</tr>
<tr>
<td>Pair 5</td>
<td>G1 embryos PTX</td>
<td>60</td>
<td>2.4167</td>
<td>1.45313</td>
<td>0.18760</td>
</tr>
<tr>
<td></td>
<td>G1 embryos</td>
<td>60</td>
<td>1.5833</td>
<td>1.51032</td>
<td>0.19498</td>
</tr>
<tr>
<td>Pair 6</td>
<td>G2 embryos PTX</td>
<td>60</td>
<td>1.3500</td>
<td>0.79883</td>
<td>0.10313</td>
</tr>
<tr>
<td></td>
<td>G2 embryos</td>
<td>60</td>
<td>1.1333</td>
<td>0.91070</td>
<td>0.11757</td>
</tr>
<tr>
<td>Pair 7</td>
<td>G3 embryos PTX</td>
<td>60</td>
<td>0.7500</td>
<td>0.79458</td>
<td>0.09295</td>
</tr>
<tr>
<td></td>
<td>G3 embryos</td>
<td>60</td>
<td>0.9167</td>
<td>0.82937</td>
<td>0.10707</td>
</tr>
<tr>
<td>Pair 8</td>
<td>ET PTX</td>
<td>60</td>
<td>2.0833</td>
<td>0.71997</td>
<td>0.09295</td>
</tr>
<tr>
<td></td>
<td>ET</td>
<td>60</td>
<td>0.8333</td>
<td>0.86684</td>
<td>0.11191</td>
</tr>
</tbody>
</table>

G1: Number of good embryos.  G2: Number of fair embryos.  G3: Number of poor embryos.  ET: Number of embryos transferred.

Using Student t-test and paired sample tests, the parameters of group IIIA was compared to the parameters of group IIIB.
Discussion

Rizk et al in a prospective randomized controlled study found that a significantly higher fertilization rate occurred in the group where spermatozoa treated with PTX compared with controls. They concluded that PTX improves the fertilization rate and outcome in couples with male factor infertility and poor fertilization rates and did not suggest any increase in or evidence of congenital malformations in pregnancies following IVF cycles where PTX was used (5). Imoedemhe et al investigated the effect of PTX in IVF cycles using 42 oocytes from 21 women and showed an increase in sperm motility but a significant decrease in the fertilization rates and embryo development (6).

In a comparative study, Sohn et al evaluated the effect of PTX on the conventional ICSI program undergone in severe asthenozoospermia on a total of 348 cycles of ICSI (7). Fertilization rate of PTX group was higher than those of ICSI programs undertaken using sperm not treated with PTX (70.6% vs. 62.9%, p<0.01) and, ET and clinical pregnancy rates of PTX group were slightly higher (93.1%, 44.2% vs. 90.3%, 36.2%). In a study of ICSI in cases with severe oligozoospermia Takeda et al stimulated sperm motility using PTX and found that fertilization and embryo recovery rates of the PTX group were significantly lower than those of the control group (8). However, the pregnancy, implantation, and abortion rates of the PTX group were not significantly different from those of the control group.

Moreover, no abnormal findings were found in babies subsequently born. They concluded that PTX treatment was effective in cases where sperm sorting was difficult. Our results showed that the fertilization rate, the number of good embryos, the number of fair embryos, the number of embryos transferred, the number of embryo sacs and the implantation rate were not significantly different when comparing group I with group II. On the other hand, the number of poor embryos was significantly higher in group II in absence of PTX addition proving that it has no embryotoxic effect. Moreover, the pregnancy rate was significantly higher in group I than that of group II, whereas the abortion rate was found non-significantly different between the two groups.

The effect of PTX was more evident when comparing group IIIA with group IIIB, where almost all the outcome parameters of ICSI (the number of oocytes fertilized, the fertilization rate, the total number of embryos, the number of good embryos and the number of embryos transferred) were found significantly higher in group IIIA (sperm portion incubated with PTX) then in group IIIB (other semen portion not incubated with PTX). Moreover, the number of poor embryos was found significantly lower in group IIIA than in group IIIB, so once again excluding that PTX has embryotoxic effects. Our results agree with the results of Rizk et al and Sohn et al as regards the positive effect of PTX on the fertilization rates, embryos quality, the number of embryos transferred and with results of the pregnancy rates (5, 7).

It also agrees with the findings of Takeda et al on the fertilization rate being higher with PTX and that the abortion rate is not significantly different when using it, however our study differs from the latter study in that the pregnancy rate was significantly higher in our study, but their study included a larger number of infertile couples (348) than ours.
and they did not do crossing over as in the present study and they worked on a different semen parameter (severe OAT) (8). On the other hand, our results contradicts with the findings of Imoedemhe et al which stated that using PTX was associated with decrease in both the fertilization rate and the embryo quality, but their study was on IVF cycles and included only 42 oocytes from 21 women (6).

We concluded that PTX has a significant positive effect on ICSI outcome in cases of mild and moderate asthenozoospermia as regards the fertilization rate, the embryos quality and the pregnancy rates without any significant embryotoxic effect or significant increase in the abortion rate. Moreover, the results are more solid when using prospective crossing over of the semen sample in each patient i.e. each patient acts as his own control. At last but not least, our study presents a conclusion that PTX can be used as a useful compound in semen samples preparation prior to oocytes injection in ICSI procedure regardless of the state of sperm motility or the degree of asthenozoospermia.

Acknowledgments

The authors thank all the staff members of Adam International Hospital and in particular those of the IVF Unit for their help and scientific support. The PTX was provided at no additional cost other than cost of the ICSI procedure itself, which the couple originally came to perform in Adam International Hospital.

Conflict of interest

None declared.

References


